Understanding When and Why Re-Consent Is Required in Clinical Trials

Informed consent is not a one-time event. As clinical trials evolve, certain circumstances may necessitate re-consenting the participant. This process—known as re-consent—is vital to maintaining transparency, ethical integrity, and regulatory compliance. In this guide, we explain the circumstances that require re-consent, the regulatory basis, and how to implement re-consent efficiently across clinical trial sites.

What Is Re-Consent?

Re-consent refers to obtaining a participant’s renewed informed consent due to significant changes in the trial or the participant’s status. These changes may affect the risk-benefit profile, trial procedures, or the participant’s eligibility to continue. Unlike initial consent, re-consent is triggered by evolving trial contexts rather than enrollment.

Why Re-Consent Is Critical:

• Maintains ethical responsibility to keep participants informed
• Ensures ongoing voluntary participation
• Meets regulatory and ICH-GCP requirements
• Documents participants’ awareness of protocol changes
• Protects against legal or compliance issues during audits

Common Scenarios Requiring Re-Consent:

1. Protocol Amendments

Significant changes in trial procedures, visit schedules, or assessments can impact participant involvement. For example, if a new imaging requirement is added, participants must be re-informed.

2. Safety Information Updates

When new risks, side effects, or warnings are identified (e.g., from DSMB reports or ongoing pharmacovigilance), all enrolled subjects should be re-consented using the revised ICF reflecting updated risk information.

3. Change in Dosing or Treatment Regimen

Any modification to the investigational product’s dosage, route, or schedule requires participant re-consent, especially when it could affect safety or efficacy outcomes.

4. Change in Legal Status

• If a participant enrolled as a minor reaches the age of majority, re-consent is needed using the adult ICF version.
• If a previously incapacitated participant regains capacity, consent must be re-obtained from the participant instead of the LAR.

5. Reopening of a Study Arm or Extension Phases

Re-consent is needed when participants are invited into long-term follow-ups or open-label extension studies that were not initially disclosed.

Regulatory Guidance on Re-Consent:

• ICH-GCP E6(R2): Emphasizes re-consent when new information becomes available
• USFDA: Requires IRB review and approval of revised ICFs for significant protocol changes
• CDSCO (India): Mandates Ethics Committee re-approval for amended ICFs and AV re-recording if applicable
• EMA: Re-consent must be clearly documented and filed in the TMF

Steps to Implement Re-Consent at the Site Level:

Step 1: Identify the Trigger

Triggers include protocol amendments, safety updates, regulatory queries, or sponsor instructions. Site staff should stay updated via Clinical Trial Management Systems (CTMS) or sponsor communication.

Step 2: Prepare Updated Consent Materials

• Draft a revised Informed Consent Form (ICF)
• Highlight new or changed information (use tracked changes)
• Submit for EC/IRB review and approval

Step 3: Train Site Staff

Before initiating re-consent, site personnel must be trained on the changes to ensure accurate explanation to participants.

Step 4: Conduct Re-Consent

• Meet with the participant (or LAR)
• Explain new information clearly
• Allow time for questions
• Document the date and time of re-consent
• Record audio-visual consent again if mandated (India-specific)

Step 5: File and Track Documentation

• Maintain updated ICF in the subject’s source file
• Log re-consent in site’s ICF tracker
• Report status in monitoring visits and GMP documentation reviews

Re-Consent Checklist for Investigators:

• Protocol or risk change assessed?
• Updated ICF approved by IRB/EC?
• Staff trained on new version?
• Re-consent obtained and dated?
• AV recording done (if applicable)?
• Documentation filed in source records and TMF?

Documentation Tools:

• ICF Version Tracker Log
• Re-Consent Audit Trail Sheet
• Consent Deviation Log
• Updated AV Consent Record (for India, as per GCP consent guidance)
• Monitoring Visit Checklists

Common Errors in Re-Consent and Their Consequences:

Best Practices for Ethical Re-Consent:

• Make re-consent conversations participant-centered
• Explain “why” re-consent is needed in simple terms
• Provide written summaries along with the ICF
• Avoid coercion; always allow time for questions
• Engage the Ethics Committee when in doubt

Conclusion:

Re-consent is a critical yet often overlooked process in clinical trial management. It reflects respect for the participant’s autonomy and adherence to evolving regulatory and ethical standards. By knowing when and why to initiate re-consent, and implementing it effectively, investigators and sponsors reinforce transparency and integrity throughout the clinical research lifecycle.